Key Takeaways:
Johnson & Johnson is walking away from the $100 billion GLP-1 weight-loss drug race, betting its diversified oncology and medical device businesses will deliver steadier returns than a rival increasingly dependent on a single drug category.
Johnson & Johnson is steering clear of the $100 billion GLP-1 weight-loss market, betting its portfolio of cancer treatments and medical devices will outperform a rival whose revenue is increasingly tied to one drug class.
"We are not going to get caught up in the hype," Chief Executive Officer Joaquin Duato said, explaining the company's decision to focus on areas where it already holds strong positions, including bone and lung cancer treatments.
The contrast with Eli Lilly is stark. Weight-loss drugs now account for nearly two-thirds of Lilly's revenue, according to company filings, leaving it exposed to pricing pressure, competition from Novo Nordisk and potential safety concerns tied to long-term GLP-1 use. JNJ generates revenue across pharmaceuticals and medical devices — surgical tools, joint replacements and other procedure-based products that face less disruptive competition.
The strategic divergence is reflected in valuation. Eli Lilly trades at more than 40 times earnings, while JNJ trades at 29 times. JNJ's dividend yield of 2.1% also exceeds Lilly's 0.6%, offering income investors a wider cushion. The question is whether JNJ's caution will prove prescient or leave it missing the biggest pharma opportunity in decades.
Oncology and Devices as Growth Levers
JNJ's oncology push includes a recent acquisition of a company with a promising prostate cancer drug candidate, adding to its existing strength in bone and lung cancer. The company is also one of the world's largest medical device makers, a segment that provides recurring demand tied to surgical procedures rather than prescription refills.
Members of Congress have been loading up on both JNJ and UnitedHealth stock, according to recent trading disclosures, signaling bipartisan confidence in the healthcare sector's defensive qualities.
GLP-1 Risks Remain Under Scrutiny
The GLP-1 market faces growing questions over long-term safety. A 2021 study funded by Novo Nordisk found that patients who stopped taking semaglutide regained two-thirds of their lost weight within a year, with cardiovascular benefits reversing as well. Gastrointestinal side effects — nausea, vomiting and diarrhea — remain the most common complaints, while more serious risks include pancreatitis and potential thyroid tumors, according to FDA labeling.
For income-focused investors, the choice may come down to yield and diversification. JNJ's 2.1% dividend, backed by a 61-year streak of increases, offers a predictable return stream. Lilly's 0.6% yield reflects its growth-stage valuation, where investors are betting on future earnings rather than current cash returns.
The divergence means JNJ shareholders are not betting on a single drug class. They are betting on a conglomerate with pricing power across multiple healthcare segments. Lilly shareholders are betting that GLP-1 drugs remain the standard of care for obesity and diabetes for years to come, with no major safety or pricing shocks.
This article is for informational purposes only and does not constitute investment advice.
